FDA approves Gavreto for NSCLC with RET gene fusions

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted regular approval to Gavreto (pralsetinib) for adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by an FDA-approved test.

Gavreto is sponsored by Genentech Inc.

Gavreto was previously granted accelerated approval for the NSCLC indication on Sept. 4, 2020, based on initial overall response rate and duration of response in 114 patients enrolled in the ARROW trial—, a multicenter, open-label, multi-cohort trial. The conversion to regular approval was based on data from an additional 123 patients and 25 months of additional follow-up to assess durability of response.

Full prescribing information for Gavreto can be found on FDA’s website.

Efficacy was demonstrated in a total of 237 patients with locally advanced or metastatic RET fusion-positive NSCLC. Patients received Gavreto until disease progression or unacceptable toxicity.

The primary efficacy measures were ORR and DOR as determined by a Blinded Independent Review Committee. Among 107 treatment-naïve patients, ORR was 78% with a median DOR of 13.4 months. Among 130 patients previously treated with platinum-based chemotherapy, ORR was 63% with a median DOR of 38.8 months.

The most common adverse reactions were musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, pyrexia, and cough.

Table of Contents

YOU MAY BE INTERESTED IN

Earlier this week, Robert F. Kennedy Jr. was confirmed as secretary of Health and Human Services amid many resignations at federal health agencies and cancellations of NIH and NCAB meetings. All of this happened at a time when the Trump administration is reportedly preparing to fire thousands of HHS workers.
FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.

When Marsha B. Henderson, former FDA Associate Commissioner of Women’s Health (1998-2019), sat down for an oral history interview upon her retirement from the agency, she could not have foreseen becoming party to a government digital purge 7 years later.  Over the past week, the Trump administration has been busy at work deleting government webpages...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login